Last Update 22 Jun 26
MYCR: Sector Downgrades And Execution Risks Will Restrain Future Upside
The latest Narrative Update on Mycronic reflects a reduced analyst price target of SEK260.25, as analysts factor in slightly lower revenue growth and profit margin assumptions, along with a modestly higher future P/E, in the context of several recent downgrades on the stock.
Analyst Commentary
Recent research on Mycronic points to a more cautious stance among several bearish analysts, who have downgraded the stock while reassessing revenue growth, margins, and valuation multiples. For you as an investor, the current debate centers on how much execution risk and cyclical sensitivity should be reflected in the share price.
Bearish Takeaways
- Bearish analysts highlight reduced revenue growth assumptions for Mycronic, suggesting that previous expectations for the order pipeline and market demand may have been set too high relative to current visibility.
- There is increased focus on profit margin assumptions, with concerns that cost pressures or pricing constraints could limit upside to earnings, which in turn affects what investors may be willing to pay on a P/E basis.
- Recent downgrades emphasize execution risk, including the ability of Mycronic to deliver on its project backlog and product roadmap without delays that could weigh on near term growth and profitability.
- With the lower consolidated price target and higher assumed future P/E, bearish analysts argue that the stock’s valuation already reflects a fair amount of long term optimism, leaving less room for error if growth or margins do not track current forecasts.
What’s in the News for Mycronic
- Mycronic received an order for an SLX mask writer from a new customer in Europe, with an order value in the range of US$6 million to US$8 million and planned delivery in the third quarter of 2026. Source: Company client announcement.
- The Board of Directors revised Mycronic’s 2026 revenue guidance, adjusting its view of net sales from SEK8.25 billion to SEK8.75 billion. Source: Corporate guidance update.
- Mycronic received an order for a customized SLX mask writer from a new customer, valued in the range of US$27 million to US$30 million, with delivery planned for 2028. Source: Company client announcement.
- An existing customer in Asia placed an order with Mycronic for an SLX mask writer, with an order value in the range of US$5 million to US$7 million and delivery planned for the second quarter of 2027. Source: Company client announcement.
Valuation Changes for Mycronic
- Fair Value: SEK260.25 is unchanged, indicating no shift in the central valuation outcome used for Mycronic.
- Discount Rate: The discount rate has fallen slightly from 6.996% to 6.979%, a small adjustment that modestly lifts the present value of future cash flows.
- Revenue Growth: The revenue growth assumption has edged down from 10.68% to 10.59%, reflecting a marginally more cautious view on Mycronic’s top line outlook.
- Net Profit Margin: The net profit margin assumption has fallen slightly from 18.12% to 17.84%, implying a modestly softer earnings profile for the forecast period.
- Future P/E: The future P/E multiple has risen slightly from 30.50x to 31.03x, suggesting a somewhat higher valuation applied to Mycronic’s forecast earnings.
Key Takeaways
- Mycronic's acquisitions and new technology launches are bolstering revenue and market position, particularly in the Global Technologies and display industries.
- Strategic geographic expansion and increased R&D investments indicate potential for long-term revenue growth and market diversification.
- The combination of tariffs, demand weakness, and currency fluctuations is leading to declining revenues and earnings instability in Mycronic's High Flex division.
Catalysts
About Mycronic- Develops, manufactures, and sells production equipment for electronics industry in Sweden, rest of Europe, the United States, other Americas, China, South Korea, rest of Asia, and internationally.
- Mycronic's recent acquisitions, such as Hprobe and RoBAT, are expected to expand its offerings in the Global Technologies division with unique technologies for testing MRAM and PCBs, potentially leading to increased revenue and strengthened market position.
- The successful launch of the Prexision 8000 Evo, a high-end machine for mask writing in the display industry, confirms alignment with industry needs, and its reception may drive future order volumes, positively impacting revenue and earnings.
- Strong growth in the company's High Volume division, particularly in the Chinese domestic market, suggests potential for increased sales and revenue growth, supported by a robust order backlog.
- Continued expansion into new regions, like Southeast Asia, for High Volume production indicates strategic geographic diversification, which may enhance revenue stability and long-term growth prospects.
- Increased R&D investments in Pattern Generators, with a focus on new product development and market opportunities such as inspection and quality control, could support long-term revenue growth and competitive positioning.
Mycronic Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Mycronic's revenue will grow by 10.6% annually over the next 3 years.
- Analysts assume that profit margins will shrink from 19.9% today to 17.8% in 3 years time.
- Analysts expect earnings to reach SEK 2.0 billion (and earnings per share of SEK 10.97) by about June 2029, up from SEK 1.7 billion today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 31.1x on those 2029 earnings, down from 36.0x today. This future PE is greater than the current PE for the GB Electronic industry at 29.2x.
- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The impact of new tariffs in the U.S. has caused delays in deliveries within the High Flex division, negatively impacting quarterly earnings by SEK 15 million and potentially affecting future revenues due to hesitation in investments.
- There is noted weakness in demand within the High Flex division, particularly in Europe, leading to a decrease in order intake by 12% and negatively impacting net sales and earnings.
- The financial outlook is uncertain due to fluctuations in exchange rates and the potential indirect effects of tariffs, which could lead to lower projected sales and impact both revenue and net margins.
- Uncertainty in the investment climate and potential hesitation to invest due to market conditions and currency fluctuations could lead to volatility in order intake and revenues, especially in divisions with shorter lead times like High Flex.
- Dependency on a limited number of customers in some divisions, such as Die Bonding in the Global Technologies division, can lead to fluctuating order intake, impacting revenue stability and earnings.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of SEK260.25 for Mycronic based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK315.0, and the most bearish reporting a price target of just SEK176.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK11.2 billion, earnings will come to SEK2.0 billion, and it would be trading on a PE ratio of 31.1x, assuming you use a discount rate of 7.0%.
- Given the current share price of SEK305.0, the analyst price target of SEK260.25 is 17.2% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Mycronic?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
